Clinical Trial: 516-010

Trial Status: Open
Disease Type: Solid Tumors All
Trial ID 516-010
Sponsor ID Mirati

A Two-Cohort, Two-Part, Phase 1, Multicenter, Open-Label, Fixed-Sequence, Drug-Drug Interaction with QTc Assessments of Sitravatinib Followed by Combination Treatment with Nivolumab in Patients with Advanced Solid Tumors.


Fairfax Office

Learn More About This Trial

Other Relevant Trials
Trial ID 516-014
Sponsor ID Mirati

A Multicenter, Open-Label, Extension Study of the Safety and Tolerability of Sitravatinib Alone or in Combination with Other Anticancer Therapies in Patients with Advanced or Metastatic Solid Malignancies

Trial ID JBI-802-101
Sponsor ID Jubilant Therapeutics

A First-in-Human, Open-Label, Dose Escalation and Expansion Study of Orally Administered JBI-802 in Patients with Advanced Solid Tumors